These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29247952)

  • 1. Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.
    He B; Yan F; Wu C
    Biomed Pharmacother; 2018 Feb; 98():95-101. PubMed ID: 29247952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
    Wang QM; Lian GY; Song Y; Huang YF; Gong Y
    Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.
    Sun JR; Zhang X; Zhang Y
    Cell Mol Biol Lett; 2019; 24():68. PubMed ID: 31844419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
    Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
    Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
    J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA NEAT1 regulate diffuse large B-cell lymphoma by targeting miR-495-3p/PD-L1 axis.
    Yuan J; Yang J; Wang R; Hao H; Li J
    Immunopharmacol Immunotoxicol; 2022 Jun; 44(3):429-436. PubMed ID: 35352617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1.
    Dong L; Huang J; Gao X; Du J; Wang Y; Zhao L
    Cancer Sci; 2022 Aug; 113(8):2888-2903. PubMed ID: 35579082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.
    Wei T; Li M; Zhu Z; Xiong H; Shen H; Zhang H; Du Q; Li Q
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):691-701. PubMed ID: 33389078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.
    Yee D; Shah KM; Coles MC; Sharp TV; Lagos D
    J Biol Chem; 2017 Dec; 292(50):20683-20693. PubMed ID: 29066622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
    Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
    Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
    Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
    Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ.
    Wang H; Yan Z; Hao J; Yang B; Wang J; Yi L; Wang X; Li S; Zhang H; Zhang S
    Thorac Cancer; 2019 Dec; 10(12):2225-2235. PubMed ID: 31625289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint.
    Zhao L; Liu Y; Zhang J; Liu Y; Qi Q
    Cell Death Dis; 2019 Sep; 10(10):731. PubMed ID: 31570691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
    Georgiou K; Chen L; Berglund M; Ren W; de Miranda NF; Lisboa S; Fangazio M; Zhu S; Hou Y; Wu K; Fang W; Wang X; Meng B; Zhang L; Zeng Y; Bhagat G; Nordenskjöld M; Sundström C; Enblad G; Dalla-Favera R; Zhang H; Teixeira MR; Pasqualucci L; Peng R; Pan-Hammarström Q
    Blood; 2016 Jun; 127(24):3026-34. PubMed ID: 27030389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
    Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
    Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
    Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.